Immuneering
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Immuneering and other ETFs, options, and stocks.About IMRX
Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis.
CEOBenjamin J. Zeskind
CEOBenjamin J. Zeskind
Employees66
Employees66
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded2008
Founded2008
Employees66
Employees66
IMRX Key Statistics
Market cap307.35M
Market cap307.35M
Price-Earnings ratio-2.68
Price-Earnings ratio-2.68
Dividend yield—
Dividend yield—
Average volume4.70M
Average volume4.70M
High today$4.82
High today$4.82
Low today$4.63
Low today$4.63
Open price$4.74
Open price$4.74
Volume129.07K
Volume129.07K
52 Week high$10.08
52 Week high$10.08
52 Week low$1.10
52 Week low$1.10
Stock Snapshot
With a market cap of 307.35M, Immuneering(IMRX) trades at $4.76. The stock has a price-to-earnings ratio of -2.68.
As of 2026-01-21, Immuneering(IMRX) stock has fluctuated between $4.63 and $4.82. The current price stands at $4.76, placing the stock +2.8% above today's low and -1.2% off the high.
The Immuneering(IMRX)'s current trading volume is 129.07K, compared to an average daily volume of 4.7M.
In the last year, Immuneering(IMRX) shares hit a 52-week high of $10.08 and a 52-week low of $1.10.
In the last year, Immuneering(IMRX) shares hit a 52-week high of $10.08 and a 52-week low of $1.10.
Analyst ratings
100%
of 6 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own IMRX. This list is generated using Robinhood data, and it’s not a recommendation.